Drug intelligence / Profile preview

AGEN1223

Development stage: Discontinued
Lead developer: Agenus
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AGEN1223 is a novel bispecific antibody developed by Agenus for the treatment of advanced solid tumors. It is designed to selectively deplete regulatory T cells (Tregs) within the tumor microenvironment by targeting two antigens co-expressed on tumor-infiltrating Tregs. This selective depletion enhances antitumor immune responses while sparing peripheral Tregs and effector T cells. The mechanism involves antibody-dependent cell-mediated cytotoxicity (ADCC) and modulation of regulatory T lymphocytes[1][2][5]. Clinical development reached Phase 1 before being discontinued for strategic business reasons[2][7].

Other names: AGEN1223AGEN-1223AGEN 1223

Targets

Tumor-infiltrating regulatory T cell dual surface markers

Beyond the preview

Go deeper on AGEN1223.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGEN1223.

Explore the full profile